Genomics will make the dream of targeted therapies a reality, which will have a massive health and economic impact. Yet most large life science enterprises, from pharma to providers, have yet to fully adopt genomics as part of their toolkit for clinical trials, development, commercialization, and diagnostics. When will these organizations adopt genomics? Is genomics good enough yet to be… Read More
Source: TechCrunch